Boehringer Ingelheim snaps up T3 Pharmaceuticals for $508m
Boehringer Ingelheim said its immune-modulatory cancer medicines will benefit from T3 Pharma's advanced technology, supporting the company's oncology…
Merck to buy Caraway Therapeutics for up to $610m
22 Nov 23Under the agreement, Merck will acquire all the outstanding shares of Massachusetts-based Caraway with earnout milestones related to…
Zevra Therapeutics wraps up acquisition of Acer Therapeutics
21 Nov 23Zevra aims to advance in the development and commercialisation of treatments for rare diseases and support patient communities…
Astellas to buy US biopharmaceutical firm Propella for $175m
16 Nov 23Astellas will obtain Propella’s lead candidate PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor intended for the treatment…
LENZ Therapeutics to merge with Graphite Bio in all-stock deal
16 Nov 23The primary focus of the combined entity's lead programmes will be on addressing presbyopia, the age-related decline in…
Telix to acquire QSAM Biosciences and its cancer therapy candidate CycloSam
14 Nov 23The proposed deal is expected to strengthen and distinguish Telix's position in providing patients with a range of…
Alfasigma wraps up acquisition of Intercept Pharmaceuticals
09 Nov 23The deal is expected to strengthen Alfasigma's pipeline, including the addition of a novel fixed-dose combination that has…
Apollo Medical to buy assets of Community Family Care Medical Group IPA
08 Nov 23CFC's scaled provider group, with over 350 primary care physicians and 500 specialists on platform, manages the medical…
PharmaDrug Closes Acqusition of Securedose Synthetics
08 Nov 23Following completion of the Transaction SecureDose became a wholly-owned subsidiary of PharmaDrug
Bristol Myers Squibb acquires Orum’s ORM-6151 programme for up to $180m
07 Nov 23ORM-6151 is an anti-CD33 antibody-enabled GSPT1 degrader intended to treat acute myeloid leukaemia (AML) and other CD33-expressing malignancies,…